Model for intracellular lamivudine metabolism in peripheral blood mononuclear cells ex vivo and in human immunodeficiency virus type 1-infected adolescents

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 8, 2006, Pages 2686-2694

  Zhou, Zexun ^a   Rodman, John H ^b   Flynn, Patricia M ^b   Robbins, Brian L ^b   Wilcox, Carrie K ^b   D'Argenio, David Z ^a  

^a University of Southern California ^*  (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADOLESCENT; ANTIVIRAL ACTIVITY; ARTICLE; BAYES THEOREM; CHRONIC DRUG ADMINISTRATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TRANSPORT; EQUILIBRIUM CONSTANT; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KINETICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHOSPHORYLATION; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; BAYES THEOREM; CROSS-OVER STUDIES; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; LEUKOCYTES, MONONUCLEAR; MODELS, BIOLOGICAL; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33746866382     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01637-05     Document Type: Article

References (37)

1. Anderson, P. L., T. N. Kakuda, S. Kawle, and C. V. Fletcher. 2003. Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals. AIDS 17:2159-2168.
2. Anderson, P. L., T. N. Kakuda, and K. A. Lichtenstein. 2004. The cellular pharmacology of nucleoside- and nucleotide-analogue reverse-transcriptase inhibitors and its relationship to clinical toxicities. Clin. Infect. Dis. 38:743-753.
3. Cabrita, M. A., S. A. Baldwin, J. D. Young, and C. E. Cass. 2002. Molecular biology and regulation of nucleoside and nucleobasc transporter proteins in eukaryotes and prokaryotes. Biochem. Cell Biol. 80:623-638.
4. Cammack, N., P. Rouse, C. L. Marr, P. J. Reid, R. E. Boehme, J. A. Coates, C. R. Penn, and J. M. Cameron. 1992. Cellular metabolism of (-) enantiomeric 2′deoxy-3′-thiacytidine. Biochem. Pharmacol. 43:2059-2064.
5. Carr, A. 2003. Toxicity of antiretroviral therapy and implications for drug development. Nat. Rev. Drug Discov. 2:624-634.
6. Chang, C. N., S. L. Doong, J. H. Zhou, J. W. Beach, L. S. Jeong, C. K. Chu, C. H. Tsai, Y. C. Cheng, D. Liotta, and R. Schinazi. 1992. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′3′- dideoxy-3′-thiacytidine, in the inhibition of hepatitis B virus replication. J. Biol. Chem. 267:13938-13942.
7. Chang, C. N., V. Skalski, J. H. Zhou, and Y. C. Cheng. 1992. Biochemical pharmacology of (+)- and (-)-2′,3′-dideoxy-3′-thiacytidine as anti-hepatitis B virus agent. J. Biol. Chem. 267:22414-22420.
8. Fletcher, C. V. 1999. Pharmacologic considerations for therapeutic success with antiretroviral agents. Infect. Dis. 33:989-995.
9. Fletcher, C. V., P. L. Andersen, T. N. Kakuda, T. W. Schacker, K. Henry, C. R. Gross, and R. C. Brundage. 2002. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS 16:551-560.
10. Furman, P. A., J. A. Fyfe, M. H. St. Clair, K. Weinhold, J. L. Rideout, G. A. Freeman, S. N. Lehrman, D. P. Bolognesi, S. Broder, H. Mitsuya, and D. W. Barry. 1986. Phosphorylation of 3′-azido-3′-deoxythymidine and selective interaction of the 5′-triphosphate with human immunodeficiency virus reverse transcriptase. Proc. Natl. Acad. Sci. USA 83:8333-8337.
11. Gallant, J. E., A. E. Rodriguez, W. G. Weinberg, B. Young, D. S. Berger, M. L. Lim, Q. Liao, L. Ross, J. Johnson, and M. S. Shaefer. 2005. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects. J. Infect. Dis. 192:1921-1930.
12. Gao, W. Y., R. Agbaria, J. S. Driscoll, and H. Mitsuya. 1994. Divergent anti-human immunodeficiency virus activity and anabolic phosphorylation of 2′,3′-dideoxynucleoside analogs in resting and activated human cells. J. Biol. Chem. 269:12633-12638.
13. Hart, G. J., D. C. Orr, C. R. Penn, H. T. Figueiredo, N. M. Gray, R. E. Boehme, and J. M. Cameron. 1992. Effects of (-)-2′-deoxy-3′- thiacytidine (3TC) 5′-triphosphate on human immunodeficiency virus reverse transcriptase and mammalian DNA polymerases alpha, beta, and gamma. Antimicrob. Agents Chemother. 36:1688-1694.
14. Hogg, R. S., K. V. Heath, B. Yip, K. J. Craib, M. V. O'Shaughnessy, M. T. Schechter, and J. S. Montaner. 1998. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 279:450-454.
15. Johnson, M. A., K. H. Moore, G. J. Yuen, A. Bye, and G. E. Pakes. 1999. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:41-66.
16. Kakuda, T. N. 2000. Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin. Ther. 22:685-708.
17. Kakuda, T. N., P. L. Anderson, and S. L. Becker. 2004. CD4 cell decline with didanosine and tenofovir and failure of triple nucleoside/nucleotide regimens may be related. AIDS 18:2442-2444.
18. Kean, E. L., A. K. Munster-Kehnel, and R. Gerardy-Schahn. 2004. CMP-sialic acid synthetase of the nucleus. Biochim. Biophys. Acta 1673:56-65.
19. Kennedy, E. P., L. F. Borkenhagen, and S. W. Smith. 1959. Possible metabolic functions of deoxycytidine diphosphate choline and deoxycytidine diphosphate ethanolamine. J. Biol. Chem. 234:1998-2000.
20. Kewn, S., G. J. Veal, P. G. Hoggard, M. G. Barry, and D. J. Back. 1997. Lamivudine (3TC) phosphorylation and drug interactions in vitro. Biochem. Pharmacol. 54:589-595.
21. Kreimeyer A., B. Schneider, R. Sarfati, A. Faraj, J. P. Sommadossi, M. Veron, and D. Deville-Bonne. 2001. NDP kinase reactivity towards 3TC nucleotides. Antivir. Res. 50:147-156.
22. Krishnan, P., J. Y. Liou, and Y. C. Cheng. 2002. Phosphorylation of pyrimidine L-deoxynucleoside analog diphosphates. J. Biol. Chem. 277:31593-31600.
23. Krishnan, P., Q. Fu, W. Lam, J. Y. Liou, G. Dutschman, and Y. C. Cheng. 2002. Phosphorylation of pyrimidine deoxynucleoside analog diphosphates. J. Biol. Chem. 277:5453-5459.
24. Lewis, W., J. F. Simpson, and R. R. Meyer. 1994. Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ. Res. 74:344-348.
25. Liou, J. Y., G. E. Dutschman, W. Lam, Z. Jiang, and Y. C. Cheng. 2002. Characterization of human UMP/CMP kinase and its phosphorylation of D-and L-form deoxycytidine analogue monophosphates. Cancer Res. 62:1624-1631.
26. Lunn, D. J., N. Best, A. Thomas, J. Wakefield, and D. Spiegel halter. 2002. Bayesian analysis of population PK/PD models: general concepts and software. J. Pharmacokin. Pharmacodyn. 29:271-307.
27. Moore, K. H., J. E. Barrett, S. Shaw, G. E. Pakes, R. Churchus, A. Kapoor, J. Lloyd, M. G. Barry, and D. Back. 1999. The pharmacokinetics of lamivudine phosphorylation in peripheral blood mononuclear cells from patients infected with HIV-1. AIDS 13:2239-2250.
28. Negredo, E., J. Moltó, D. Burger, P. Viciana, E. Ribero, R. Paredes, M. Juan, L. Ruiz, J. Puig, A. Pruvost, J. Grassi, E. Masmitja, and B. Clotet. 2004. Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 18:459-463.
29. Palella, F. J., Jr., K. M. Delaney, A. C. Moorman, M. O. Loveless, J. Fuhrer, G. A. Satten, D. J. Aschman, and S. D. Holmberg. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N. Engl. J. Med. 338:853-860.
30. Robbins, B. L., T. T. Tran, F. H. Pinkerton, F. Akeb, R. Guedj, J. Grassi, D. Lancaster, and A. Fridland. 1998. Development of a new cartridge radioimmunoassay for determination of intracellular levels of lamivudine triphosphate in the peripheral blood mononuclear cells of human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 42:2656-2660.
31. Robbins, B. L., C. K. Wilcox, A. Fridland, and J. H. Rodman. 2003. Metabolism of tenofovir and didanosine in quiescent or stimulated human peripheral blood mononuclear cells. Pharmacotherapy 23:695-701.
32. Rodman, J. H., B. L. Robbins, J. Martinez, J. C. Lindsay, J. F. Rodriguez, and P. M. Flynn. 2003. Intracellular phosphorylation of zidovudine and lamivudine in PBMCs from HIV-1 infected adolescents on once versus twice daily regimen, p 110. In Proceedings of the 10th Conference on Retroviruses and Opportunistic Infections, Boston, Mass.
33. Rodman, J. H., B. L. Robbins, Z. Zhou, C. L. Wilcox, E. F. Neal, and D. Z. D'Argenio. 2005. Abstr. 6th Int. Workshop Clin. Pharmacol. HIV Ther., abstr. 47.
34. Rodman, J. H., B. Robbins, P. M. Flynn, and A. Fridland. 1996. A systemic and cellular model for zidovudine plasma concentrations and intracellular phosphorylation in patients. J. Infect. Dis. 174:490-499.
35. Solas, C., Y. F. Li, M. Y. Xie, J. P. Sommadossi, and X. J. Zhou. 1998. Intraccllular nucleotides of (-)-2′,3′-deoxy-3′-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus. Antimicrob. Agents Chemother. 42:2989-2995.
36. Tornevik, Y., B. Jacobsson, S. Britton, and S. Eriksson. 1991. Intracellular metabolism of 3′-azidothymidine in isolated human peripheral blood mononuclear cells. AIDS Res. Hum. Retrovir. 7:751-759.
37. Vance, D. E. 1983. Metabolism of glycerolipids, sphingolipids, and prostaglandins, p. 505-544. In G. L. Zubay (ed.), Biochemistry. Addison-Wesley Publishing Co. Inc., Reading, Mass.